{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:11:22Z","timestamp":1788448282734,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T00:00:00Z","timestamp":1516838400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00105-017-4117-y","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T14:26:39Z","timestamp":1516890399000},"page":"116-120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Lichenoide Arzneimittelreaktionen","Lichenoid drug reactions"],"prefix":"10.1007","volume":"69","author":[{"given":"H. F.","family":"Merk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vanstreels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Megahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,25]]},"reference":[{"key":"4117_CR1","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1111\/j.1365-4632.2006.03182.x","volume":"45","author":"C Ajith","year":"2006","unstructured":"Ajith C, Dogra S, Handa S (2006) Lichen planus pemphigoides associated with Ramipril. Int J Dermatol 45:1453\u20131455","journal-title":"Int J Dermatol"},{"issue":"2","key":"4117_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/15569527.2016.1206556","volume":"36","author":"I An","year":"2017","unstructured":"An I, Demir V, Akdeniz S (2017) Lichenoid drug eruption induced by colchicine: case report. Cutan Ocul Toxicol 36(2):199\u2013200","journal-title":"Cutan Ocul Toxicol"},{"key":"4117_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2008.09.032","volume":"61","author":"A Asarch","year":"2009","unstructured":"Asarch A, Gottlieb AB, Lee J, Masterpol KS, Scheinman PL, Stadecker MJ, Massarotti EM, Bush ML (2009) Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-\u03b1 antagonists. J\u00a0Am Acad Dermatol 61:104\u2013111","journal-title":"J Am Acad Dermatol"},{"key":"4117_CR4","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceforf J, Nebozhun M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, Piha-Paul SA, Yearly J, Seiwert TY, Ribas A, McClanahan TK (2017) IFN-\u03b3 related mRNA profile predicts clinical response to PD-1 blockade. J\u00a0Clin Invest 127:2930\u20132940","journal-title":"J Clin Invest"},{"issue":"4","key":"4117_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.mcna.2010.04.001","volume":"94","author":"AJ Bircher","year":"2010","unstructured":"Bircher AJ, Scherer K (2010) Delayed cutaneous manifestations of drug hypersensitivity. Med Clin North Am 94(4):711\u2013725","journal-title":"Med Clin North Am"},{"key":"4117_CR6","first-page":"97","volume-title":"Skin reactions to drugs","author":"DP Bruynzeel","year":"1998","unstructured":"Bruynzeel DP, Maibach HI (1998) Patch testing in systemic drug eruptions. In: Kauppinen K, Alanko K, Hannuksela M, Maibach H (Hrsg) Skin reactions to drugs. CRC Press, Boca Raton, S\u00a097\u2013109"},{"issue":"1","key":"4117_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.0022-202X.2003.22108.x","volume":"122","author":"M Carrozzo","year":"2004","unstructured":"Carrozzo M, Uboldi de Capei M, Dametto E, Fasano ME, Arduino P, Broccoletti R, Vezza D, Rendine S, Curtoni ES, Gandolfo S (2004) Tumor necrosis factor-alpha and interferon-gamma polymorphisms contribute to susceptibility to oral lichen planus. J\u00a0Invest Dermatol 122(1):87\u201394","journal-title":"J Invest Dermatol"},{"issue":"1","key":"4117_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/DAD.0000000000000587","volume":"39","author":"S Chou","year":"2017","unstructured":"Chou S, Hwang SJ, Carlos G, Wakade D, Fernandez-Penas P (2017) Histologic assessment of lichenoid dermatitis observed in patients with advanced malignancies on antiprogramed cell death-1 (anti-PD-1) therapy with or without Ipilimumab. Am J Dermatopathol 39(1):23\u201327","journal-title":"Am J Dermatopathol"},{"key":"4117_CR9","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/ced.13235","volume":"42","author":"AA El-Rifaie","year":"2017","unstructured":"El-Rifaie AA, Rashed LA, Doss RW, Osman ST (2017) MicroRNAs in cutaneous lichen planus. Clin Exp Dermatol 42:896\u2013901","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"4117_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2165\/11634590-000000000-00000","volume":"13","author":"C Fessa","year":"2012","unstructured":"Fessa C, Lim P, Kossard S, Richards S, Pe\u00f1as PF (2012) Lichen planus-like drug eruptions due to \u03b2\u2011blockers: a\u00a0case report and literature review. Am J Clin Dermatol 13(6):417\u2013420","journal-title":"Am J Clin Dermatol"},{"key":"4117_CR11","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s00228-017-2325-0","volume":"73","author":"G Fortuna","year":"2017","unstructured":"Fortuna G, Aria M, Schiavo JH (2017) Drug induced oral lichenoid reactions: a\u00a0real clinical entitiy? A systematic review. Eur J Clin Pharmacol 73:1523\u20131537","journal-title":"Eur J Clin Pharmacol"},{"issue":"6116","key":"4117_CR12","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1136\/bmj.1.6116.816-a","volume":"1","author":"RW Gange","year":"1978","unstructured":"Gange RW, Jones EW (1978) Bullous lichen planus caused by labetalol. Br Med\u00a0J 1(6116):816\u2013817","journal-title":"Br Med J"},{"issue":"4\u20135","key":"4117_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/BF00332566","volume":"11","author":"E Gleichmann","year":"1991","unstructured":"Gleichmann E, Kubicka-Muranyi M, Kind P, Goldermann R, Goerz G, Merk H, Rau R (1991) Insights into the mechanism of gold action provided by immunotoxicology: biooxidation of gold(I) to gold(III) detected by sensitized T\u2011cells. Rheumatol Int 11(4\u20135):219\u2013220","journal-title":"Rheumatol Int"},{"issue":"3","key":"4117_CR14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2340\/0001555573220222","volume":"73","author":"R Goldermann","year":"1993","unstructured":"Goldermann R, Schuppe HC, Gleichmann E, Kind P, Merk H, Rau R, Goerz G (1993) Adverse immune reactions to gold in rheumatoid arthritis: lack of skin reactivity. Acta Derm Venereol 73(3):220\u2013222","journal-title":"Acta Derm Venereol"},{"key":"4117_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15686","author":"N Gonzales","year":"2017","unstructured":"Gonzales N, Patel P, Han G (2017) A dissimalar biosimilar?: Lichenoid drug eruption induced by an infliximab biosimilar. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.15686","journal-title":"Br. J. Dermatol."},{"key":"4117_CR16","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.det.2012.06.016","volume":"30","author":"JW Hagen","year":"2012","unstructured":"Hagen JW, Magro CM, Crowson AN (2012) Emerging adverse cutaneous drug reactions. Dermatol Clin 30:695\u2013730","journal-title":"Dermatol Clin"},{"key":"4117_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0190-9622(08)81845-2","volume":"29","author":"S Halevy","year":"1993","unstructured":"Halevy S, Sandbank M, Livni E (1993) Macrophage migration inhibition factor release in lichenoid drug reactions. J\u00a0Am Acad Dermatol 29:263\u2013265","journal-title":"J Am Acad Dermatol"},{"key":"4117_CR18","first-page":"119","volume-title":"Skin reactions to drugs","author":"S Halevy","year":"1998","unstructured":"Halevy S (1998) In vitro tests for adverse drug reactions based on cytokine release. In: Kauppinen K, Alanko K, Hannuksela M, Maibach H (Hrsg) Skin reactions to drugs. CRC Press, Boca Raton, S\u00a0119\u2013131"},{"key":"4117_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","volume":"60","author":"L Hofmann","year":"2016","unstructured":"Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, G\u00f6ppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60:190\u2013120","journal-title":"Eur J Cancer"},{"issue":"1","key":"4117_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3109\/15569527.2015.1015725","volume":"35","author":"MRA Hussein","year":"2016","unstructured":"Hussein MRA (2016) Drug-induced skin reactions: a\u00a0pathologist viewpoint. Cutan Ocul Toxicol 35(1):67\u201379","journal-title":"Cutan Ocul Toxicol"},{"issue":"3","key":"4117_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","volume":"74","author":"SJ Hwang","year":"2016","unstructured":"Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, Carlino MS, Kefford R, Fernandez-Penas P (2016) Cutaneous adverse events (Aes) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J\u00a0Am Acad Dermatol 74(3):455\u2013461","journal-title":"J Am Acad Dermatol"},{"key":"4117_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ad.2016.05.019","volume":"108","author":"SJE Hwang","year":"2017","unstructured":"Hwang SJE, Anforth R, Carlos G, Fernandez-Penas P (2017) Cutaneous adverse events of new anti-melanoma therapies: classification and management. Actas Dermosifiliogr 108:6\u201316","journal-title":"Actas Dermosifiliogr"},{"key":"4117_CR23","series-title":"Curr Probl Dermatol","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000478081","volume-title":"Adverse reactions to biologics","author":"SJE Hwang","year":"2018","unstructured":"Hwang SJE, Fern\u00e1ndez-Pe\u00f1as P (2018) Adverse reactions to biologics: melanoma (Ipilimumab, Novolumab, Pembrolizumab). In: Puig L, Gulliver W (Hrsg) Adverse reactions to biologics. Curr Probl Dermatol, Bd. 53. Karger, Basel, S 82\u201392"},{"key":"4117_CR24","first-page":"25","volume-title":"Skin reactions to drugs","author":"K Kauppinen","year":"1998","unstructured":"Kauppinen K, Kariniemi AL (1998) Clinical manifestations and histological characteristics. In: Kauppinen K, Alanko K, Hannuksela M, Maibach H (Hrsg) Skin reactions to drugs. CRC Press, Boca Raton, S\u00a025\u201350"},{"key":"4117_CR25","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1365-4632.2009.04062.x","volume":"48","author":"JS Lehman","year":"2009","unstructured":"Lehman JS, Tollefson MM, Gibson LE (2009) Lichen planus. Int J Dermatol 48:682\u2013694","journal-title":"Int J Dermatol"},{"key":"4117_CR26","series-title":"Curr Probl Dermatol","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000478072","volume-title":"Adverse reactions to biologics","author":"SJ Lockwood","year":"2018","unstructured":"Lockwood SJ, Prens LM, Kimball AB (2018) Adverse reactions to biologics in psoriasis. In: Puig L, Gulliver W (Hrsg) Adverse reactions to biologics. Curr Probl Dermatol, Bd. 53. Karger, Basel, S\u00a01\u201314"},{"key":"4117_CR27","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1056\/NEJMcpc1512457","volume":"374","author":"ME Lorenzo","year":"2016","unstructured":"Lorenzo ME, Carter JB, Barnes JA, Nazarian RM (2016) Case 19-2016: a 65-year-old man with end-stage renal disease and a\u00a0pruritic rash. N\u00a0Engl J Med 374:2478\u20132488","journal-title":"N Engl J Med"},{"issue":"6","key":"4117_CR28","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.clindermatol.2015.09.006","volume":"33","author":"MJ Payette","year":"2015","unstructured":"Payette MJ, Weston G, Humphrey S, Yu J, Holland KE (2015) Lichen planus and other lichenoid dermatoses: kids are not just little people. Clin Dermatol 33(6):631\u2013643","journal-title":"Clin Dermatol"},{"key":"4117_CR29","series-title":"Curr Probl Dermatol","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000479475","volume-title":"Adverse reactions to biologics","author":"L Puig","year":"2018","unstructured":"Puig L (2018) Paradoxical reactions: anti-tumor necrosis factor \u03b1 agents, ustekinumab, secukinumab, ixekizumab, and others. In: Puig L, Gulliver W (Hrsg) Adverse reactions to biologics. Curr Probl Dermatol, Bd. 53. Karger, Basel, S 49\u201363"},{"issue":"4","key":"4117_CR30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/cup.12666","volume":"43","author":"KB Schaberg","year":"2016","unstructured":"Schaberg KB, Novoa RA, Wakelee HA, Kim J, Cheung C, Srinivas S, Kwong BY (2016) Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J\u00a0Cutan Pathol 43(4):339\u2013334","journal-title":"J Cutan Pathol"},{"issue":"1","key":"4117_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/15569527.2010.521225","volume":"30","author":"T Skare","year":"2011","unstructured":"Skare T, Ribeiro CF, Souza FHM, Haendchen L, Jord\u00e3o JM (2011) Antimalarial cutaneous side effects: a\u00a0study in 209 users. Cutan Ocul Toxicol 30(1):45\u201349","journal-title":"Cutan Ocul Toxicol"},{"issue":"8194","key":"4117_CR32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(80)92006-1","volume":"2","author":"R Staughton","year":"1980","unstructured":"Staughton R, Sutton R, Farrell M (1980) beta-Blockers, autoimmunity, and rashes. Lancet 2(8194):581","journal-title":"Lancet"},{"issue":"1","key":"4117_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3109\/15569527.2012.702837","volume":"32","author":"B Turk","year":"2013","unstructured":"Turk B, Gunaydin A, Ertam I, Ozturk G (2013) Adverse cutaneous drug reactions among hospitalized patients: five year surveillance. Cutan Ocul Toxicol 32(1):41\u201345","journal-title":"Cutan Ocul Toxicol"},{"issue":"1","key":"4117_CR34","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3109\/15569527.2016.1160101","volume":"36","author":"Y Zheng","year":"2017","unstructured":"Zheng Y, Zhang J, Chen H, Lai W, Maibach HI (2017) Terbinafine-induced lichenoid drug eruption. Cutan Ocul Toxicol 36(1):101\u2013103","journal-title":"Cutan Ocul Toxicol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-017-4117-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-017-4117-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-017-4117-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T18:08:37Z","timestamp":1693505317000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-017-4117-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,25]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["4117"],"URL":"https:\/\/doi.org\/10.1007\/s00105-017-4117-y","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,25]]},"assertion":[{"value":"25 January 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.F.\u00a0Merk, L.\u00a0Vanstreels und M.\u00a0Megahed geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren. Alle Patienten, die \u00fcber Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben. Im Falle von nicht m\u00fcndigen Patienten liegt die Einwilligung eines Erziehungsberechtigten oder des gesetzlich bestellten Betreuers vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}